GlassScriptPhysician profile
Emmanuel U Agoh
NPI 1508034927
$9,683.50
in general payments reported to CMS, 2019-2025
39 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,236 · 2020: $1,246 · 2021: $1,378 · 2022: $1,129 · 2023: $1,310 · 2024: $823 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,853.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,719.18 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $751.25 | 2023-2025 | |
| Pfizer INC. | $692.27 | 2019-2023 | |
| Gilead Sciences, INC. | $522.10 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $407.94 | 2020-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.30 | 2019-2025 | Jardiance |
| Viiv Healthcare Company | $336.83 | 2019-2021 | |
| Lilly USA, LLC | $301.27 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sunovion Pharmaceuticals INC. | $295.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $290.66 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.90 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $224.25 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $205.42 | 2019-2021 | |
| Novo Nordisk INC | $188.46 | 2022-2025 | Ozempic, Rybelsus |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $154.93 | 2019-2023 | Hetlioz |
| Abbvie INC. | $146.49 | 2023-2025 | Mavyret |
| Teva Pharmaceuticals USA, INC. | $123.16 | 2019 | |
| Dexcom, INC. | $122.71 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $85.66 | 2023-2024 | Gemtesa |
| Amgen INC. | $84.39 | 2019-2021 | |
| Esperion Therapeutics, INC. | $83.87 | 2021-2025 | Nexletol |
| Viatris Specialty LLC | $80.80 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.26 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $39.14 | 2025 | Spinosad, Natroba |
| Hologic Sales and Service, LLC | $37.13 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $35.06 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $34.51 | 2022 | |
| Phathom Pharmaceuticals, INC. | $33.53 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $23.56 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $22.41 | 2023 | Krystexxa |
| Ironwood Pharmaceuticals, INC | $21.92 | 2022 | |
| Medtronic, INC. | $16.94 | 2025 | Inceptiv |
| Mylan Specialty L.P. | $16.63 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.26 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.53 | 2023 | Ztlido |
| Eisai INC. | $13.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.92 | 2019 | |
| Allergan, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Agoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.